利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.033 秒)

    Methods of regulating cytokine signalling
    1.
    发明申请
    Methods of regulating cytokine signalling 审中-公开
    调节细胞因子信号传导的方法

    公开(公告)号：US20080057517A1

    公开(公告)日：2008-03-06

    申请号：US11818589

    申请日：2007-06-15

    申请人： Sandra Nicholson ,  Manuel Baca ,  Nicos Nicola ,  Douglas Hilton ,  Jian Zhang ,  Louis Fabri ,  Andrew Nash

    发明人： Sandra Nicholson ,  Manuel Baca ,  Nicos Nicola ,  Douglas Hilton ,  Jian Zhang ,  Louis Fabri ,  Andrew Nash

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6863

    摘要： The present invention relates generally to a method for regulating cytokine signalling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signalling (SOCS) interaction in controlling cytokine signalling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signalling. Control of cytokine signalling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.

    摘要翻译： 本发明一般涉及用于调节细胞因子信号传导的方法和可用于其的试剂。 本发明的方法部分地基于在控制细胞因子信号传导中识别细胞因子信号传导抑制剂（SOCS）相互作用的分子靶标。 分子靶标的鉴定允许开发测定以筛选可用于调节细胞因子功能的一系列激动剂和拮抗剂。 因此，本发明进一步提供用于SOCS-受体相互作用的激动剂和拮抗剂的筛选测定和更特别的高通量筛选测定。 这样的激动剂和拮抗剂可用于制备用于控制细胞因子信号传导的药物。 细胞因子信号传导的控制对于治疗一系列病症（包括癌症，炎性病症，免疫学障碍和涉及信号转导异常的任何其他病症）是重要的。

    Monoclonal antibody against Interleukin-13 receptor alpha 1 (IL-13Ralpha1)
    2.
    发明申请
    Monoclonal antibody against Interleukin-13 receptor alpha 1 (IL-13Ralpha1) 有权
    白细胞介素-13受体α1单克隆抗体（IL-13Rα1）

    公开(公告)号：US20050058645A1

    公开(公告)日：2005-03-17

    申请号：US10850270

    申请日：2004-05-20

    申请人： Felicity Dunlop ,  Manuel Baca ,  Andrew Nash ,  Louis Fabri ,  Douglas Hilton ,  Nicos Nicola

    发明人： Felicity Dunlop ,  Manuel Baca ,  Andrew Nash ,  Louis Fabri ,  Douglas Hilton ,  Nicos Nicola

    IPC分类号： C07K16/28 ,  C12N5/20 ,  A61K39/395 ,  C07K16/24

    CPC分类号： C07K16/2866 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2319/00

    摘要： The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13Rα1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13Rα1/ligand interaction is also provided.

    摘要翻译： 本发明一般涉及结合白细胞介素-13受体α1链（IL-13Rα1）并通过IL-13和/或IL-4拮抗IL-13受体介导的信号传导的抗体。 更具体地说，本发明为哺乳动物，特别是IL-13Rα1提供人源化或人抗体。 这些抗体在治疗或预防IL-13和/或IL-4介导的疾病或病症中具有应用。 本发明进一步考虑通过施用受试者抗体调节IL-13和/或IL-4介导的疾病或病症的方法。 本发明还提供了可用于鉴定通过IL-13受体复合物调节IL-13和/或IL-4信号传导的抗体或其它试剂的测定系统。 因此，还提供了筛选IL-13Rα1/配体相互作用的调节剂的方法。

    Methods of regulating cytokine signalling
    5.
    发明授权
    Methods of regulating cytokine signalling 失效
    调节细胞因子信号传导的方法

    公开(公告)号：US07256007B2

    公开(公告)日：2007-08-14

    申请号：US10221125

    申请日：2001-03-09

    申请人： Sandra Elaine Nicholson ,  Manuel Baca ,  Nicos A. Nicola ,  Douglas Hilton ,  Jian Guo Zhang ,  Louis Fabri ,  Andrew Nash

    发明人： Sandra Elaine Nicholson ,  Manuel Baca ,  Nicos A. Nicola ,  Douglas Hilton ,  Jian Guo Zhang ,  Louis Fabri ,  Andrew Nash

    IPC分类号： G01N33/53 ,  G01N33/00 ,  C07K1/00 ,  C07K14/00

    CPC分类号： G01N33/6863

    摘要： The present invention relates generally to a method for regulating cytokine signaling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signaling (SOCS) interaction in controlling cytokine signaling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signaling. Control of cytokine signaling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.

    摘要翻译： 本发明一般涉及用于调节细胞因子信号传导的方法和可用于其的试剂。 本发明的方法部分地基于在控制细胞因子信号传导中识别细胞因子信号传导抑制剂（SOCS）相互作用的分子靶标。 分子靶标的鉴定允许开发测定以筛选可用于调节细胞因子功能的一系列激动剂和拮抗剂。 因此，本发明进一步提供用于SOCS-受体相互作用的激动剂和拮抗剂的筛选测定和更特别的高通量筛选测定。 这样的激动剂和拮抗剂可用于制备用于控制细胞因子信号传导的药物。 细胞因子信号传导的控制对于治疗一系列病症（包括癌症，炎性病症，免疫学障碍和涉及信号转导异常的任何其他病症）是重要的。

    Nucleic acid encoding alpha chain of human IL-11 receptor
    10.
    发明申请
    Nucleic acid encoding alpha chain of human IL-11 receptor 失效

    公开(公告)号：US20060051842A1

    公开(公告)日：2006-03-09

    申请号：US11204563

    申请日：2005-08-16

    申请人： Douglas Hilton

    发明人： Douglas Hilton

    IPC分类号： C07H21/04 ,  C12P21/06 ,  C07K14/715

    CPC分类号： C07K14/715

    摘要： The present invention relates generally to novel haemopoietin receptors, or components or parts thereof and to a method for cloning genetic sequences encoding same. More particularly, the subject invention is directed to recombinant or synthetic haemopoietin receptors or components or parts thereof. The receptor molecules or components or parts thereof and their genetic sequences of the present invention are useful in the development of a wide range agonists, antagonists and therapeutics and diagnostic reagents based on ligand interaction with its receptor.